Immutep disclosed that an independent data monitoring committee recommended stopping the Phase III TACTI‑004 study of eftilagimod alfa (efti) in first‑line non‑small‑cell lung cancer for futility. The company reported the decision and said it will wind down the trial while it conducts a comprehensive review of the data, triggering a near‑total collapse in its share price. Marc Voigt, Immutep’s CEO, described the outcome as “very disappointed and surprised,” underscoring the clinical and commercial stakes for LAG‑3 immunotherapies. The readout reverberates across checkpoint‑modulator programs: efti had shown earlier positive signals in smaller trials and was being evaluated as a chemo‑sparing immune enhancer paired with PD‑1 therapy. The Phase III futility call removes a late‑stage de‑risking event for Immutep and forces investors and partners to reassess LAG‑3 portfolios and combination strategies. The company now faces program and balance‑sheet decisions as it analyzes the incomplete dataset.